A U.S. senator is trying to lower prices for medicines that are discovered with taxpayer dollars, and his effort amounts to a new twist to unraveling a complicated controversy that has embroiled the U.S. Department of Defense, large drug makers, numerous lawmakers, and consumer groups.

Late last month, Angus King (I-Maine) successfully added an amendment to a Defense Department funding bill that consumer groups say would effectively allow an end run around drug makers that priced products — which were developed with taxpayer dollars — higher than what is charged in seven other countries. The trigger would be determined by median prices and per capita income compared with the U.S.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I believe Shrek will go for the well known ” Reverse Prozac Defense”. His lawyer will argue that subtherapuetic levels of fluoxetine in Bro’s blood caused him to commit the alleged deeds.

  • Hmm – Sanofi ” not pursuing the project for a “commercial return.” May I observe that I have my doubts?
    One is reminded of the old saw ‘”We are a non-profit corporation. That wasn’t the plan … it’s just the way things turned out.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy